Novartis v Novosys: Delhi HC Enforces Cadila Doctrine in Pharma Trademark

In Novartis AG & Anr. v. Novosys Life Sciences Private Limited & Anr. [CS(COMM) 404/2026, C.O. (COMM.IPD-TM) 128/2026 & C.O. (COMM.IPD-TM) 129/2026], the Intellectual Property Division of the High Court of Delhi decreed a multi-proceeding trademark infringement action and dual cancellation petitions in favour of Swiss healthcare giant Novartis AG. Reaffirming the strict public interest standard governing pharmaceutical trademarks under Cadila Health Care and enforcing the binding injunction equivalent of court undertakings under Noorali Babul Thanewala, the Court restrained the defendant from using the deceptively similar mark ‘NOVOSYS’, mandated the immediate cancellation of three registered trademarks, directed the withdrawal of pending applications, and ordered the delisting of infringing medicinal products across digital supply chains.

The Pharmaceutical Trademark Conflict: Novartis vs Novosys in Classes 05 and 35

Struggling to understand Trademark Law? Read our complete Trademark Law Guide.

The plaintiffs, Novartis AG and its Indian operating subsidiary Novartis Healthcare Private Limited, filed CS(COMM) 404/2026 asserting absolute proprietary exclusivity over the mark ‘NOVARTIS’. Adopted globally in 1996, the mark has enjoyed statutory registration in India under registration no. 700020 in Class 05 dating back to February 28, 1996, alongside international registration IRDI-3050272 dated April 28, 2015. Reinforcing its towering commercial standing, ‘NOVARTIS’ was formally notified in the list of well-known trademarks by the Registrar of Trade Marks in Trade Marks Journal No. 2144 on February 19, 2024. Through extensive worldwide and domestic sales, rigorous clinical research, and extensive marketing, the mark had acquired immense commercial goodwill, signifying uncompromised pharmaceutical precision.

The dispute arose when the plaintiffs discovered that defendant Novosys Life Sciences Private Limited, incorporated on February 19, 2019, and operating out of Dhanas, Chandigarh, had entered the pharmaceutical market under the mark ‘NOVOSYS’. The defendant deployed ‘NOVOSYS’ not merely as a product trademark for allopathic medicinal preparations in Class 05, but also as its corporate identity and online commercial portal via ‘www.novosyslifesciences.com’. Furthermore, the defendant secured defensive registrations on the Trade Marks Register, obtaining registration nos. 4279942 in Class 05 and 4279944 in Class 35, alongside registration no. 5760118 for ‘LINOVOSYS’ in Class 05, while prosecuting pending application nos. 6775168 and 6775169.

Novartis initiated statutory cease and desist correspondence on May 21, 2025, followed by a rejoinder on July 29, 2025. When out-of-court demands failed to elicit voluntary abandonment, Novartis approached the Delhi High Court. Novartis established that ‘NOVOSYS’ was structurally, visually, and phonetically deceptively similar to ‘NOVARTIS’. Both marks shared the identical, highly prominent prefix ‘NOVO-‘, possessed similar syllabic rhythms, and were applied to identical categories of therapeutic preparations. Because these medicinal products flowed through overlapping distribution pipelines, encompassing wholesale distributors, hospital procurement networks, neighborhood retail chemists, and e-pharmacy platforms, the structural collision generated a severe probability of initial interest confusion and trade-source misattribution.

The Cadila Health Care Doctrine: Why Stricter Confusion Standards Govern Medicinal Products

Although the litigation culminated in a consent-driven decree based on sworn undertakings, Hon’ble Mr. Justice Purushaindra Kumar Kaurav situated the judicial analysis within the seminal public safety jurisprudence articulated by the Supreme Court of India in Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd. (2001) 5 SCC 73. The Court emphasized that pharmaceutical trademark conflicts cannot be treated as ordinary commercial turf battles between private merchants.

However, in view of the course adopted by the defendant, it is not necessary for this Court to return any finding on the competing claims of the parties with respect to deceptive similarity, infringement or passing off, and this Court refrains from doing so.

Hon’ble Mr. Justice Purushaindra Kumar Kaurav, High Court of Delhi

The doctrinal rationale expounded in Cadila Health Care dictates that courts must apply a lesser degree of proof when evaluating confusing similarity between pharmaceutical marks as compared to non-medicinal merchandise. The underlying premise is uncompromising: drugs are therapeutic chemicals, not harmless confectionery. Confusion between medicinal products carries catastrophic public health hazards, including adverse drug interactions, therapeutic failure, toxic overdoses, and death. In India, this heightened scrutiny is further necessitated by linguistic diversity, varying levels of literacy, the prevalence of semi-literate pharmacy assistants, hurried medical practitioners drafting illegible handwritten prescriptions, and overcrowded chemist shops where oral requests are routinely misheard.

The High Court actively applied this protective doctrine when scrutinizing the defendant’s request for commercial accommodation. While the defendant sought an expansive eight-month period to exhaust pre-manufactured stock committed to institutional supply contracts, the Court curtailed this timeline to three months. The Court reasoned that under the Cadila framework, medicines bearing infringing or confusing trade dress and nomenclature must not linger in commercial circulation any longer than strictly necessary, subordinating private commercial convenience to public health imperatives.

The Sanctity of Judicial Undertakings: Binding Effect Under Noorali Babul Thanewala and Rama Narang

A critical legal dimension of the decree lies in the procedure under Order XXIII Rule 3 read with Order XII Rule 6 of the Code of Civil Procedure, 1908 (CPC). Following receipt of advance notice, the defendant made initial statements before the Court on April 17, 2026, expressing a desire to relinquish ‘NOVOSYS’. It subsequently submitted formal undertakings via affidavits dated April 25, 2026, and May 10, 2026. The defendant confirmed cessation of manufacturing, surrendered the disputed branding, changed its corporate name to ‘SYSOWN LIFE SCIENCES PRIVATE LIMITED’ with Registrar of Companies approval, disabled its website, and consented to the expunction of its registrations.

The undertakings of the defendant, read together, answer each of the reliefs claimed in paragraph nos. 51(i) to 51(v) of the plaint. The relief of damages has been given up by the plaintiffs, and no other issue survives which would require the parties to be relegated to trial.

Hon’ble Mr. Justice Purushaindra Kumar Kaurav, High Court of Delhi

The Court anchored the enforceability of these sworn affidavits in two landmark Supreme Court authorities. In Noorali Babul Thanewala v. K.M.M. Shetty (1990) 1 SCC 259, the Supreme Court ruled that when a court accepts a formal undertaking tendered by a litigant and passes an order predicated upon it, that order amounts in substance to an injunction. A breach of such an undertaking is directly punishable as civil contempt under the Contempt of Courts Act, 1971. Complementing this, the Supreme Court held in Rama Narang v. Ramesh Narang (2006) 11 SCC 114 that a consent decree possesses identical legal validity and force as an adjudicated decree, because the Court appends its formal judicial mandate to the agreement of the parties.

Relying on the recent Supreme Court decision in Rajiv Ghosh v. Satya Naryan Jaiswal (2025 SCC OnLine SC 751), Justice Kaurav noted that unequivocal party admissions on affidavit satisfy the substantial subject matter of the dispute under Order XXIII Rule 3 CPC, empowering the court to pronounce immediate judgment under Order XII Rule 6 CPC. For Novartis, accepting these undertakings yielded decisive, ironclad relief: immediate complete brand surrender and corporate renaming without the procedural delays, evidentiary burdens, and financial collection risks inherent in a prolonged trial.

Consolidation of Civil Infringement Suits and High Court Rectification Petitions (IPD Mechanics)

The judgment highlights the structural efficiency achieved by the Delhi High Court Intellectual Property Division (IPD) created pursuant to the Delhi High Court Intellectual Property Rights Division Rules, 2022. Prior to the Tribunals Reforms Act, 2021, an IP owner confronted with an infringing defendant holding a defensive trademark registration faced a bifurcated legal nightmare. The civil suit for infringement had to be filed in the District Court or High Court, while the rectification action to cancel the defendant’s registered mark had to be initiated before the Intellectual Property Appellate Board (IPAB), resulting in parallel proceedings, conflicting orders, and chronic procedural gridlock.

Under the IPD mechanism, Novartis filed CS(COMM) 404/2026 alongside two independent rectification petitions: C.O. (COMM.IPD-TM) 128/2026 (targeting registration no. 4279944 in Class 35) and C.O. (COMM.IPD-TM) 129/2026 (targeting registration no. 4279942 in Class 05). Because the IPD bench exercised concurrent civil and statutory supervisory jurisdiction, Justice Kaurav consolidated all three matters into a single adjudication.

Following the precedent established in GlaxoSmithKline Pharmaceuticals Ltd. v. Akums Drugs and Pharmaceuticals Ltd. (2022:DHC:4495), the Court exercised its powers under Sections 47 and 57 of the Trade Marks Act, 1999, to issue direct, peremptory commands to the Registrar of Trade Marks, who was impleaded as Respondent No. 2. The Court directed the statutory authority to expunge registration nos. 4279944, 4279942, and 5760118 (‘LINOVOSYS’) from the Register, while treating pending application nos. 6775168 and 6775169 as formally withdrawn. This consolidated mechanism extinguished the defendant’s statutory shields in a single hearing, purging the Register without administrative friction.

E-Commerce Intermediary Liability and the Challenge of Stray Online Listings

A persistent operational hurdle for brand proprietors in modern trademark litigation involves the digital afterlife of infringing merchandise. During proceedings on May 14, 2026, counsel for Novartis placed on record several third-party B2B and e-commerce listings displaying the defendant’s products under the ‘NOVOSYS’ mark. The defendant maintained that it was not privy to these digital listings, asserting that they were generated independently by downstream stockists, third-party aggregators, or automated directory scraping.

Addressing this challenge in paragraph 19 of the decision, Justice Kaurav granted Novartis express liberty to independently approach intermediaries, digital platforms, and online marketplaces, directing that the intermediaries ‘shall do the needful’. This directive dovetails with safe harbour jurisprudence governed by Section 79 of the Information Technology Act, 2000, read alongside the Information Technology (Intermediary Guidelines and Digital Media Ethics Code) Rules, 2021.

Under the doctrine settled in Shreya Singhal v. Union of India (2015) 5 SCC 1, intermediaries lose statutory immunity if they fail to expeditiously remove unlawful content upon receiving ‘actual knowledge’ through a formal court order. By securing express liberty within the decree sheet, Novartis obtained an effective enforcement instrument. Rather than joining dozens of retail platforms to the suit, Novartis can issue takedown notices to e-commerce portals such as IndiaMART, 1mg, PharmEasy, and TradeIndia, accompanied by the certified decree. Intermediaries receiving this judicial mandate must deactivate offending URLs within statutory time limits, preventing the circulation of residual digital inventory.

Also Read: Karnataka HC Sets Aside Injunction: ‘Section 34’ Protects Prior Users

Commercial Brand Protection Playbook: Lessons for Pharma In-House Counsel

The swift, comprehensive resolution of the Novartis v. Novosys litigation offers several critical operational takeaways for general counsel and pharmaceutical brand protection managers:

First, pharmaceutical enterprises must execute proactive, multi-tier brand clearance searches before adopting marks incorporating common pharmaceutical prefixes like ‘NOVO-‘, ‘NOV-‘, or ‘SYS-‘. While these prefixes often derive from chemical nomenclature or Latin roots (‘novus’ meaning new), their adoption in proximity to renowned marks such as ‘NOVARTIS’ or ‘NOVO NORDISK’ creates acute litigation exposure. Pre-launch surveillance must extend beyond class-specific register searches to encompass common law market use, state drug licensing databases, and MCA company name registries.

Second, brand owners must synchronize civil infringement plaints with simultaneous Section 57 rectification petitions before the High Court IPD. An infringer holding a subsisting registration possesses statutory immunity against infringement actions under Section 28(3) and Section 30(2)(e) of the Trade Marks Act, 1999, confining the plaintiff solely to an action for passing off. By coupling the suit with rectification petitions in the IPD, plaintiffs dismantle the defendant’s statutory shield, ensuring total register purging in one unified decree.

Third, corporate brand owners must adopt pragmatic enforcement postures regarding existing stock exhaustion. Where public health risks are controlled and the infringer demonstrates good faith through immediate corporate renaming and domain deactivation, granting a strictly time-bound run-off for pre-manufactured batches (three months, as calibrated by the Court) avoids years of protracted trial. In exchange, the plaintiff secures a complete permanent injunction, corporate identity surrender, domain transfer, and register cancellation, while saving substantial litigation expenditure.

Finally, in-house legal teams should mandate that all settlement terms and party admissions be embodied in detailed affidavits sworn by authorized corporate directors. As reinforced by Noorali Babul Thanewala, an undertaking tendered to the Court carries the immediate threat of contempt sanctions, giving brand owners ultimate operational leverage to safeguard their pharmaceutical trademarks across India.